drugset / Trial / NCT01093326

Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis

NCT01093326

Phase 2 Completed 353 enrolled Actelion
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is an extension to the study AC-058B201 and will investigate the long-term safety, tolerability and efficacy of ponesimod in patients with relapsing-remitting multiple sclerosis.

Timeline

Start
2010-05-12
Primary completion
2023-09-06
Completion
2023-09-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Ponesimod Small molecule 10 mg Oral
Subject Ponesimod Small molecule 20 mg Oral
Subject Ponesimod Small molecule 40 mg Oral